産(chǎn)品開發轉化
1.2019新(xīn)型冠狀病毒熒光PCR法檢測技(jì )術、抗體(tǐ)檢測技(jì )術和基因沾染檢測方法轉讓。
1.The transfers of 2019 Novel Coronavirus Fluorescent PCR Detection Technology, Antibody Detection Technology, and Gene Contamination Detection Method Transfer.
1.1. 2020年2月，與北京卓誠惠生生物(wù)科(kē)技(jì )股份有(yǒu)限公(gōng)司共同研發的新(xīn)型冠狀病毒2019-nCoV核酸檢測試劑盒（熒光PCR法）獲得國(guó)家醫(yī)療器械批件（國(guó)械注準20203400179），該試劑盒于2020年5月被列入世界衛生組織應急使用(yòng)清單。
1.1 In February 2020, in collaboration with Beijing Applied Biological Technologies Co., Ltd., the novel coronavirus (2019-nCoV) nucleic acid detection kit (fluorescent PCR method) was granted the National Medical Device Approval (Approval No. 20203400179). By May 2020, this kit was listed in the World Health Organization's Emergency Use List (EUL).
1.2. 新(xīn)型冠狀病毒IgM和IgG抗體(tǐ)檢測試劑盒成功獲批，與核酸檢測聯合用(yòng)于患者的快速診斷和篩查工(gōng)作(zuò)。2021年，試劑盒參加了國(guó)家“十三五”科(kē)技(jì )創新(xīn)成就展。
1.2. The detection kits for the novel coronavirus IgM and IgG antibodies were approved, combined with nucleic acid tests for expedited patient diagnosis and screening. In 2021, the kit was featured in the National 13th Five-Year Plan Science and Technology Innovation Achievement Exhibition.
圖.新(xīn)冠病毒IgM抗體(tǐ)檢測試劑盒
Novel Coronavirus IgM Antibody DetectionKit
圖.新(xīn)冠病毒IgG抗體(tǐ)檢測試劑盒
Novel Coronavirus IgG Antibody Detection Kit
1.3.開發“新(xīn)型冠狀病毒（SARS-CoV-2）相關環境污染源檢測試劑盒（TaqMan探針法）”，用(yòng)于排除科(kē)研機構和疫苗接種場所中(zhōng)存在的假病毒，擴增子，疫苗株等污染，彌補現有(yǒu)新(xīn)型冠狀病毒檢測方法的局限，對精(jīng)準防控疫情、穩定經濟社會秩序提供有(yǒu)力手段。
1.3. The "SARS-CoV-2 Environmental Contamination Source Detection Kit (TaqMan Probe Method)" were developed. This kit targets standard laboratory marker genes and traits of deactivated vaccines, formulating respective detection strategies that negate false viral signals, amplifications, and vaccine strains prevalent in research entities and vaccination locales. It remedies the constraints of current SARS-CoV-2 detection techniques and is instrumental for precise epidemic control and maintenance of socio-economic order.
圖.新(xīn)型冠狀病毒（SARS-CoV-2）相關環境污染源檢測試劑盒（TaqMan探針法）SARS-CoV-2
SARS-CoV-2 Environmental Contamination Source Detection Kit (TaqMan Probe Method)
2.“高效抗艾滋病病毒（HIV）多(duō)肽”相關研究成果于2016年10月與山(shān)西康寶生物(wù)制品股份有(yǒu)限公(gōng)司簽署了技(jì )術轉讓及合作(zuò)協議書，轉化金額2000萬。該項目已經完成臨床I期，準備進入II期臨床。
2.In October 2016, the research results related to "Highly effective anti-HIV peptide" developed by researcher He Yuxian of Institute of Pathogen Biology and Center for AIDS Research, Chinese Academy of Medical Sciences and Peking Union Medical College, signed a technology transfer and cooperation agreement with Shanxi Kangbao Biological Products Company Limited, with an amount of 20 million. The project has completed clinical phase I and is ready to enter phase II.
3.“廣譜冠狀病毒膜融合抑制劑多(duō)肽藥物(wù)”相關研究成果于2022年1月成功轉讓悅康藥業集團股份有(yǒu)限公(gōng)司，轉化金額5000萬。目前該項目已經完成臨床I期，進入II/III期臨床。
3.The research result of "Broad-spectrum Coronavirus Membrane Fusion Inhibitor Peptide Drug" developed by researcher He Yuxian of Institute of Pathogen Biology and Center for AIDS Research, Chinese Academy of Medical Sciences and Peking Union Medical College, was successfully transferred to Youcare Pharmaceutical Group in January 2022, with an amount of 50 million dollars. Currently, the project has completed clinical phase I and entered phase II/III.
